ASA Not Best Antiplatelet in Established CAD: Meta-Analysis at AshTip Solution.

AshTip NewsLetter |The antiplatelet of choice for long-term, secondary prevention for patients with established coronary artery disease (CAD) may well be a P2Y12 inhibitor such as clopidogrel or ticagrelor rather than aspirin, suggests a patient-level meta-analysis of seven randomized trials.

Medscape

ASA Not Best Antiplatelet in Established CAD: Meta-Analysis

ASA Not Best Antiplatelet in Established CAD: Meta-Analysis

The antiplatelet of choice for long-term, secondary prevention for patients with established coronary artery disease (CAD) may well be a P2Y12 inhibitor such as clopidogrel or ticagrelor rather than aspirin, suggests a patient-level meta-analysis of seven randomized trials.